Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds.

@article{CastilloCarranza2014SpecificTO,
  title={Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds.},
  author={Diana Laura Castillo-Carranza and Julia E. Gerson and Urmi Sengupta and Marcos Jair Guerrero-Munoz and Cristian A. Lasagna-Reeves and Rakez Kayed},
  journal={Journal of Alzheimer's disease : JAD},
  year={2014},
  volume={40 Suppl 1},
  pages={
          S97-S111
        }
}
Neurodegenerative disease is one of the greatest health crises in the world and as life expectancy rises, the number of people affected will continue to increase. The most common neurodegenerative disease, Alzheimer's disease, is a tauopathy, characterized by the presence of aggregated tau, namely in the form of neurofibrillary tangles. Historically, neurofibrillary tangles have been considered the main tau species of interest in Alzheimer's disease; however, we and others have shown that tau… 
View on PubMed
content.iospress.com
119 Citations
Highly Influential Citations
4
Background Citations
41
Methods Citations
11
Results Citations
4

Figures from this paper

119 Citations

Citation Type

Citation Type

Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy
TLDR
Results indicate that targeting tau oligomers is beneficial for a mouse model of synucleinopathy and may be a viable therapeutic strategy for treating diseases in which tau and α-synuclein have a synergistic toxicity.
Tau Oligomers Derived from Traumatic Brain Injury Cause Cognitive Impairment and Accelerate Onset of Pathology in Htau Mice.
TLDR
It is found that tau oligomers form as a result of brain injury in two different models of TBI, and these oligomers accelerated onset of cognitive deficits when injected into brains of Htau mice.
Oligomeric tau-targeted immunotherapy in Tg4510 mice
TLDR
The data suggest that there is some exposure of the Tg4510 mouse brain to TOMA, but it was inadequate to affect the phenotype in these mice at the doses used, consistent with other observations that the rapidly depositing Tg 4510 mouse is a challenging model in which to demonstrate efficacy of tau-lowering treatments compared to some other preclinical models of t Tau deposition/overexpression.
Tau Immunotherapy Modulates Both Pathological Tau and Upstream Amyloid Pathology in an Alzheimer's Disease Mouse Model
TLDR
The results suggest that tau oligomerization is not only a consequence of Aβ pathology but also a critical mediator of the toxic effects observed afterward in AD, and support the potential of t Tau oligomers as a therapeutic target for AD.
Cerebral Microvascular Accumulation of Tau Oligomers in Alzheimer’s Disease and Related Tauopathies
TLDR
It is found that tau oligomers accumulate in cerebral microvasculature of human patients with AD and PSP, in association with vascular endothelial and smooth muscle cells, and this findings add to the growing evidence for multifaceted microvascular involvement in the pathogenesis of AD and other neurodegenerative diseases.
In Vivo Validation of a Small Molecule Inhibitor of Tau Self-Association in htau Mice
TLDR
The results validated the screening approach by showing that targeting tau self-association can inhibit the entire tau aggregation pathway by using the selected and optimized lead compound whose activity translated from in vitro and cellular assays to an in vivo model of t Tau aggregation.
The role of tau oligomers in the onset of Alzheimer's disease neuropathology.
TLDR
The recent advances in tau oligomer research are discussed, their implications on AD and other tauopathies, the mechanisms of tau turnover by the principal protein clearance systems (the proteasome and autophagy), and the potential use of tAU oligomers as drug targets for the development of new therapeutic approaches are discussed.
Near Infrared Light Treatment Reduces Synaptic Levels of Toxic Tau Oligomers in Two Transgenic Mouse Models of Human Tauopathies
TLDR
Exposure to near infrared (NIR) light decreases levels of endogenous toxic tau oligomers and alleviate associated memory deficits, thus furthering the development of NIR light as a possible therapeutic for AD.
Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies
TLDR
It is shown that the di-phenyl-pyrazole anle 138b binds to aggregated tau and inhibits tau aggregation in vitro and in vivo and that reducing tau aggregates with anle138b may represent an effective and promising approach for the treatment of human tauopathies.
Tau Oligomers Neurotoxicity
TLDR
The most recent literature on the damaging effect of TauOs on the stability of the genome and the function of the nucleus, energy production and mitochondrial function, cell signaling and synaptic plasticity, the microtubule assembly, neuronal cytoskeleton and axonal transport, and the effectiveness of the protein degradation system are summarized.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 56 REFERENCES
Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice
TLDR
It is reported that oligomers of recombinant full-length human tau protein are neurotoxic in vivo after subcortical stereotaxic injection into mice, and suggests that tau oligomers induce neurodegeneration by affecting mitochondrial and synaptic function, both of which are early hallmarks in AD and other tauopathies.
Accumulation of Pathological Tau Species and Memory Loss in a Conditional Model of Tauopathy
TLDR
Accumulation of early-stage aggregated tau species, before the formation of NFT, is associated with the development of functional deficits during the pathogenic progression of tauopathy, suggesting that NFTs are not the major neurotoxic tau protein species, at least during the early stages of pathogenesis.
Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer's disease brain.
Identification of oligomers at early stages of tau aggregation in Alzheimer's disease
TLDR
A novel tau oligomer‐specific antibody is engineered and used to elucidate the temporal course and biochemical features of oligomers during NFT development in AD brain and highlight the suitability of tAU oligomers as therapeutic targets in AD and related tauopathies.
Tau aggregates as immunotherapeutic targets.
TLDR
Recent advances in this new field are summarized, the role of tau oligomers and their potential as a therapeutic target for the treatment of AD and other neurodegenerative tauopathies are highlighted, and the challenges that lie ahead are discussed.
Age-Dependent Impairment of Cognitive and Synaptic Function in the htau Mouse Model of Tau Pathology
TLDR
The results suggest that tau pathology may underlie an age-dependent learning impairment through disruption of synaptic function in htau mice that preceded neurodegeneration.
Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model
Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models
TLDR
It is demonstrated that peripheral administration of two antibodies against pathological Tau forms significantly reduces biochemical Tau pathology in the JNPL3 mouse model and significantly delays the onset of motor function decline and weight loss.
Soluble pathological tau in the entorhinal cortex leads to presynaptic deficits in an early Alzheimer’s disease model
TLDR
The hypothesis that misfolded and hyperphosphorylated tau can impair neuronal function within the entorhinal-hippocampal network, even prior to frank NFT formation and overt neurodegeneration is supported.
Preparation and characterization of neurotoxic tau oligomers.
TLDR
It is shown that both Aβ and α-synuclein oligomers induce tau aggregation and the formation of β-sheet-rich neurotoxic tau oligomers.
...
1
2
3
4
5
...